Drug manufacturer Venus Remedies today said its research product 'Mebatic', useful in treatment of waterborne diseases, has got sales and manufacturing approvals from the Drugs Controller General of India (DCGI).
The company has got permission from DCGI for marketing and manufacturing of Mebatic, Venus said in a statement to the Bombay Stock Exchange (BSE).
"This product is intended to be used in infusion form as one of the best solutions for treatment of problems associated with waterborne bacterial/plasmodial pathogens in humans," the company said.
Shares of Venus Remedies surged over 6 per cent and were trading at Rs 294 in the afternoon trade on the BSE.
